Document is current
Any future updates will be listed below
-
Authors
Shima, Yoshihito https://orcid.org/0000-0002-2523-2938
Uchida-Yamada, Mona https://orcid.org/0000-0002-5781-9485
Motegi, Sei-ichiro https://orcid.org/0000-0001-8286-0669
Shimada, Taku
Ishii, Haruka
Ohya, Yoshito
Kanai, Yasumasa https://orcid.org/0009-0005-0300-4917
-
Funding
Funding for this research was provided by:
Kyowa Kirin Co., Ltd.
- License Information
-
More Information
Article History
Received: 23 September 2024
Accepted: 17 January 2025
First Online: 5 February 2025
Declarations
:
: Yoshihito Shima received grants or contracts from Kobayashi Pharmaceutical Co., Ltd, payment and honoraria for lectures and presentations from Asahi Kasei Pharma Corporation, Chugai Pharmaceutical Co., Ltd, and GSK plc. Sei-ichiro Motegi received grants or contracts from Taiho Pharmaceutical Co., Ltd, Sun Pharma Japan Ltd, Novartis Parma K.K., Kaken Pharmaceutical Co., Ltd, Eli Lilly Japan K.K and Maruho Co., Ltd., and honoraria for lectures and presentations from Janssen Pharmaceutical K.K., Eli Lilly Japan K.K, AbbVie G.K., Sanofi K.K., Daiichi Sankyo Co., Ltd., Leo Pharma, Kyowa Kirin, Co., Ltd., Nobelpharma Co., Ltd., Maruho Co., Ltd., Tori Pharmaceutical Co. Ltd., Kaken Pharmaceutical Co., Ltd, Eisai Co., Ltd., Taiho Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., and Sato Yakuhin Kogyo Co. Ltd. Mona Uchida-Yamada, Taku Shimada, Haruka Ishii, and Yasumasa Kanai are employees of Kyowa Kirin Co., Ltd. Mona Uchida-Yamada, Taku Shimada, Haruka Ishii, and Yoshito Ohya own stock in Kyowa Kirin Co., Ltd.
: All respondents gave informed consent before participation. All personnel involved in this study adhered to the Declaration of Helsinki and the Ethical Guidelines for Medical and Biological Research Involving Human Subjects. The Research Ethical Review Committee of Kyowa Kirin Co., Ltd. approved (approval number: EC_0105) this study, which was registered under the clinical trial registration number UMIN000050368.
